Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E3112 in Japanese healthy adult males
NCT03922633Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Apr 2019
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olamepermin alfa in ulcerative colitis (UC) (8 cohorts), sponsored by EA Pharma Co., Ltd. Primary endpoints: Serum Concentration of E3112 at Day 8, Peak Concentration at Day 8 and 6 more. Started Apr 2019; status: completed.
02
Drugs
olamepermin alfa
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03922633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03922633.